Carfilzomib-induced endothelial dysfunction, recovery of proteasome activity, and prediction of cardiovascular complications: a prospective study
Efstathios Kastritis, Ageliki Laina, Georgios Georgiopoulos, Maria Gavriatopoulou, Eleni‐Dimitra Papanagnou, Evangelos Eleutherakis‐Papaiakovou, Despina Fotiou, Nikolaos Kanellias, Ioanna Dialoupi, Nikolaos Makris, Efstathios Manios, Magdalini Migkou, Μαρία Ρούσσου, Maria Kotsopoulou, Konstantinos Stellos, Evangelos Terpos, Ioannis P. Trougakos, Κimon Stamatelopoulos, Meletios Α. Dimopoulos
Topics & Concepts
CarfilzomibMedicineBrachial arteryInternal medicineAdverse effectProspective cohort studyEndothelial dysfunctionMultiple myelomaProteasome inhibitorBiomarkerBlood pressureGastroenterologyBiologyBiochemistryMultiple Myeloma Research and TreatmentsProtein Degradation and InhibitorsCancer Treatment and Pharmacology